IgE antibodies are crucially involved in mediating, maintaining and amplifying the allergic cascade. The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Anti-IgE inhibits allergic responses by binding to serum IgE, thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. Randomized clinical trials showed relevant clinical effects of omalizumab including improvements of respiratory symptoms and quality of life. Moreover, a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators was also observed. Omalizumab is relatively well tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for most severe patients with persistent allergic asthma, inadequately controlled by high doses of standard treatments.

An insight into pharmacological and clinical basis of anti-IgE for add-on therapy of severe asthma

VATRELLA, Alessandro;
2013

Abstract

IgE antibodies are crucially involved in mediating, maintaining and amplifying the allergic cascade. The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Anti-IgE inhibits allergic responses by binding to serum IgE, thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. Randomized clinical trials showed relevant clinical effects of omalizumab including improvements of respiratory symptoms and quality of life. Moreover, a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators was also observed. Omalizumab is relatively well tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for most severe patients with persistent allergic asthma, inadequately controlled by high doses of standard treatments.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11386/4406853
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact